Letermovir acts as an orally or i.v administered cytomegalovirus terminus complex inhibitor, antiviral agent, used in the treatment of CMV infection which is prevalent in those with immunocompromised systems.
Letermovir (AIC246) is an orally active, potent and selective human cytomegalovirus (HCMV) DNA terminase complex inhibitor th at blocks HCMV replication (EC50 = 0.9-3.1 nM among 17 clinial HCMV isolates; EC50 = 1.6-3.9 nM against 6 AD169-derived drug-resistant variants) by interfering with viral DNA cleavage/packaging. Letermovir exhibits little potency toward MCMV (Smith), RCMV (Maastricht), VZV (Oka), HSV-1 (166v VP22-GFP), HSV-2 (01-6332), HHV-6 (typeA-GS) or EBV (B95-8) (MCMV EC50 = 4.5 μM, all other EC50 >10 μM).
